Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Breast Cancer | Review

Recent advances in therapeutic strategies for triple-negative breast cancer

Authors: Yun Li, Huajun Zhang, Yulia Merkher, Lin Chen, Na Liu, Sergey Leonov, Yongheng Chen

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC is a highly heterogeneous cancer with specific mutations and aberrant activation of signaling pathways. Hence, targeted therapies, such as those targeting DNA repair pathways, androgen receptor signaling pathways, and kinases, represent promising treatment options against TNBC. In addition, immunotherapy has also been demonstrated to improve overall survival and response in TNBC. In this review, we summarize recent key advances in therapeutic strategies based on molecular subtypes in TNBC.
Literature
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98.PubMedPubMedCentralCrossRef
3.
4.
Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19(6):608–15.PubMedPubMedCentralCrossRef
5.
Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750–67.PubMedPubMedCentralCrossRef
6.
Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, et al. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020;11(1):2350.PubMedPubMedCentralCrossRef
7.
Lehmann B, Jovanović B, Chen X, Estrada M, Johnson K, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11(6):e0157368.PubMedPubMedCentralCrossRef
8.
Burstein M, Tsimelzon A, Poage G, Covington K, Contreras A, Fuqua S, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98.PubMedCrossRef
9.
Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35(3):428-40.e5.PubMedCrossRef
10.
Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015;17:43.PubMedPubMedCentralCrossRef
11.
Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–42.PubMedCrossRef
12.
Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 2012;14(4):R110.PubMedPubMedCentralCrossRef
13.
Lee J, Yost S, Yuan Y. Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges. Cancers. 2020;12(6):1404.PubMedCentralCrossRef
14.
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232–45.PubMedCrossRef
15.
Konecny G. Cyclin-dependent kinase pathways as targets for women’s cancer treatment. Curr Opin Obstet Gynecol. 2016;28(1):42–8.PubMedCrossRef
16.
Yamamoto T, Kanaya N, Somlo G, Chen S. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer. Breast Cancer Res Treat. 2019;174(3):615–25.PubMedPubMedCentralCrossRef
17.
Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Ther Adv Med Oncol. 2018;10:1758835918818346.PubMedPubMedCentralCrossRef
18.
Patel J, Goss A, Garber J, Torous V, Richardson E, Haviland M, et al. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020;6:19.PubMedPubMedCentralCrossRef
19.
20.
Wen W, Marcinkowski E, Luyimbazi D, Luu T, Xing Q, Yan J, et al. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer. Cells. 2019;8(9):1010.PubMedCentralCrossRef
21.
Lemjabbar-Alaoui H, Peto C, Yang Y, Jablons D. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020;10(8):2649–76.PubMedPubMedCentral
22.
Rugo H, Roche H, Thomas E, Chung H, Lerzo G, Vasyutin I, et al. Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: a pooled analysis from two large phase II, randomized clinical trials. Clin Breast Cancer. 2018;18(6):489–97.PubMedCrossRef
23.
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33(17):1902–9.PubMedPubMedCentralCrossRef
24.
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24(5):628–37.PubMedPubMedCentralCrossRef
25.
Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33(17):1895–901.PubMedPubMedCentralCrossRef
26.
von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56.CrossRef
27.
Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378–85.PubMedPubMedCentralCrossRef
28.
Yu K, Ye F, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1390–6.PubMedCrossRef
29.
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13–21.PubMedCrossRef
30.
Wu X, Tang P, Li S, Wang S, Liang Y, Zhong L, et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nat Commun. 2018;9(1):832.PubMedPubMedCentralCrossRef
31.
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16(4):436–46.PubMedCrossRef
32.
Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44.PubMedCrossRef
33.
Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38(5):388–94.PubMedCrossRef
34.
Rugo HS, Olopade OI, DeMichele A, Yau C, van’T Veer LJ, Buxton MB, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New Engl J Med. 2016;375(1):23–34.PubMedCrossRef
35.
Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497–509.PubMedCrossRef
36.
Vinayak S, Tolaney S, Schwartzberg L, Mita M, McCann G, Tan A, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132.PubMedPubMedCentralCrossRef
37.
Konstantinopoulos P, Barry W, Birrer M, Westin S, Cadoo K, Shapiro G, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20(4):570–80.PubMedPubMedCentralCrossRef
38.
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884–90.PubMedPubMedCentralCrossRef
39.
Xu M, Yuan Y, Yan P, Jiang J, Ma P, Niu X, et al. Prognostic significance of androgen receptor expression in triple negative breast cancer: a systematic review and meta-analysis. Clin Breast Cancer. 2020;20(4):e385–96.PubMedCrossRef
40.
Gucalp A, Tolaney S, Isakoff S, Ingle J, Liu M, Carey L, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505–12.PubMedPubMedCentralCrossRef
41.
Zhou M, Zheng H, Li Y, Huang H, Min X, Dai S, et al. Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment. Aging. 2021;13(5):6982–98.PubMedPubMedCentralCrossRef
42.
Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12–1). Annals Oncol. 2016;27(5):812–8.CrossRef
43.
Yuan Y, Lee J, Yost S, Frankel P, Ruel C, Egelston C, et al. A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer. Oncologist. 2021;26(2):99-e217.PubMedCrossRef
44.
Gonzalez-Angulo A, Stemke-Hale K, Palla S, Carey M, Agarwal R, Meric-Berstam F, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15(7):2472–8.PubMedCrossRef
45.
Shah S, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9.PubMedCrossRef
46.
Stemke-Hale K, Gonzalez-Angulo A, Lluch A, Neve R, Kuo W, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Can Res. 2008;68(15):6084–91.CrossRef
47.
Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Annals Oncol. 2020;31(3):377–86.CrossRef
48.
Garrido-Castro A, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020;22(1):120.PubMedPubMedCentralCrossRef
49.
Martín M, Chan A, Dirix L, O’Shaughnessy J, Hegg R, Manikhas A, et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Annals Oncol. 2017;28(2):313–20.CrossRef
50.
Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036–47.PubMedPubMedCentralCrossRef
51.
Zhao H, Yang Q, Hu Y, Zhang J. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triplenegative breast cancer cells. Oncol Rep. 2018;40(6):3223–34.PubMedPubMedCentral
52.
Matulonis U, Wulf G, Barry W, Birrer M, Westin S, Farooq S, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Annals Oncol. 2017;28(3):512–8.CrossRef
53.
Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18(10):1360–72.PubMedPubMedCentralCrossRef
54.
Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho J, et al. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Annals Oncol. 2019;30(8):1289–97.CrossRef
55.
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38(5):423–33.PubMedCrossRef
56.
Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, et al. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Sci Rep. 2021;11(1):82.PubMedPubMedCentralCrossRef
57.
Juric D, Castel P, Griffith M, Griffith O, Won H, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature. 2015;518(7538):240–4.PubMedCrossRef
58.
Brigham & Women’s Hospital & Harvard Medical School Chin Lynda 9 11 Park Peter J. 12 Kucherlapati Raju 13, Genome data analysis: Baylor College of Medicine Creighton Chad J. 22 23 Donehower Lawrence A. 22 23 24 25, Institute for Systems Biology Reynolds Sheila 31 Kreisberg Richard B. 31 Bernard Brady 31 Bressler Ryan 31 Erkkila Timo 32 Lin Jake 31 Thorsson Vesteinn 31 Zhang Wei 33 Shmulevich Ilya 31, Oregon Health & Science University Anur Pavana 37 Spellman Paul T. 37. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Sep 23;490(7418):61–70.
59.
Wang W, Oguz G, Lee PL, Bao Y, Wang P, Terp MG, et al. KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer. J Exp Med. 2018;215(11):2833–49.PubMedPubMedCentralCrossRef
60.
Muellner M, Uras I, Gapp B, Kerzendorfer C, Smida M, Lechtermann H, et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol. 2011;7(11):787–93.PubMedPubMedCentralCrossRef
61.
Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona F, et al. PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition. Cancer Cell. 2016;30(2):229–42.PubMedPubMedCentralCrossRef
62.
Lacal P, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol Res. 2018;136:97–107.PubMedCrossRef
63.
Barton MK. Bevacizumab in neoadjuvant chemotherapy increases the pathological complete response rate in patients with triple-negative breast cancer. CA Cancer J Clin. 2014;64(3):155–6.PubMedCrossRef
64.
Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, et al. BRCA1/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto study. J Clin Oncol. 2018;36(22):2281–7.PubMedPubMedCentralCrossRef
65.
Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 2014;143(1):141–51.PubMedCrossRef
66.
Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer. 2020;8(1):e000696.PubMedPubMedCentralCrossRef
67.
Diamond J, Eckhardt S, Pitts T, van Bokhoven A, Aisner D, Gustafson D, et al. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018;20(1):82.PubMedPubMedCentralCrossRef
68.
Yang X, Phillips D, Ferguson A, Nelson W, Herman J, Davidson N. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Can Res. 2001;61(19):7025–9.
69.
Tan W, Allred J, Moreno-Aspitia A, Northfelt D, Ingle J, Goetz M, et al. Phase I study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients. Clin Breast Cancer. 2016;16(2):82–6.PubMedCrossRef
70.
Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, et al. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019;10(1):5114.PubMedPubMedCentralCrossRef
71.
72.
Zhang X, Kang L, Ding L, Vranic S, Gatalica Z, Wang Z. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 2011;30(7):770–80.PubMedCrossRef
73.
Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, et al. Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nat Med. 2018;24(4):463–73.PubMedPubMedCentralCrossRef
74.
Livasy C, Karaca G, Nanda R, Tretiakova M, Olopade O, Moore D, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathol. 2006;19(2):264–71.CrossRef
75.
Canonici A, Browne A, Ibrahim M, Fanning K, Roche S, Conlon N, et al. Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. Therap Adv Med Oncol. 2020;12:1758835919897546.
76.
Finn R, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss L, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011;17(21):6905–13.PubMedCrossRef
77.
Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005;23(23):5323–33.PubMedCrossRef
78.
Liao W, Ho Y, Lin Y, Naveen Raj E, Liu K, Chen C, et al. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater. 2019;86:395–405.PubMedCrossRef
79.
Pearson A, Smyth E, Babina I, Herrera-Abreu M, Tarazona N, Peckitt C, et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 2016;6(8):838–51.PubMedPubMedCentralCrossRef
80.
Turner N, Lambros M, Horlings H, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013–23.PubMedPubMedCentralCrossRef
81.
82.
83.
Wu D, Guo M, Min X, Dai S, Li M, Tan S, et al. LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance. Chem Commun. 2018;54(85):12089–92.CrossRef
84.
Shao M, Chen X, Yang F, Song X, Zhou Y, Lin Q, et al. Design, synthesis, and biological evaluation of aminoindazole derivatives as highly selective covalent inhibitors of wild-type and gatekeeper mutant FGFR4. J Med Chem. 2022;65(6):5113–33.PubMedCrossRef
85.
Guo M, Duan Y, Dai S, Li J, Chen X, Qu L, et al. Structural study of ponatinib in inhibiting SRC kinase. Biochem Biophys Res Commun. 2022;598:15–9.PubMedCrossRef
86.
Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018;19(6):812–24.PubMedCrossRef
87.
Liu D, Guo P, McCarthy C, Wang B, Tao Y, Auguste D. Peptide density targets and impedes triple negative breast cancer metastasis. Nat Commun. 2018;9(1):2612.PubMedPubMedCentralCrossRef
88.
Rhodes L, Short S, Neel N, Salvo V, Zhu Y, Elliott S, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Can Res. 2011;71(2):603–13.CrossRef
89.
Jiang Y, Liu Y, Xiao Y, Hu X, Jiang L, Zuo W, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31(2):178–86.PubMedCrossRef
90.
Synnott N, Murray A, McGowan P, Kiely M, Kiely P, O’Donovan N, et al. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer. 2017;140(1):234–46.PubMedCrossRef
91.
Cai D, Wang J, Gao B, Li J, Wu F, Zou JX, et al. RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nat Commun. 2019;10(1):4621.PubMedPubMedCentralCrossRef
92.
Ouyang L, Zhang L, Fu L, Liu B. A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer. Autophagy. 2017;13(4):777–8.PubMedPubMedCentralCrossRef
93.
Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med. 2017;9(401).
94.
Hatem E, Azzi S, El Banna N, He T, Heneman-Masurel A, Vernis L, et al. Auranofin/vitamin C: a novel drug combination targeting triple-negative breast cancer. J Natl Cancer Inst. 2019;111(6):597–608.PubMedCrossRef
95.
Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Can Res. 2009;69(4):1302–13.CrossRef
96.
Creighton C, Li X, Landis M, Dixon J, Neumeister V, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106(33):13820–5.PubMedPubMedCentralCrossRef
97.
Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.PubMedPubMedCentralCrossRef
98.
Shipitsin M, Campbell L, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259–73.PubMedCrossRef
99.
Bierie B, Moses H. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506–20.PubMedCrossRef
100.
Bhola N, Balko J, Dugger T, Kuba M, Sánchez V, Sanders M, et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Investig. 2013;123(3):1348–58.PubMedPubMedCentralCrossRef
101.
Padua D, Zhang X, Wang Q, Nadal C, Gerald W, Gomis R, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77.PubMedPubMedCentralCrossRef
102.
Harrison H, Farnie G, Howell S, Rock R, Stylianou S, Brennan K, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Can Res. 2010;70(2):709–18.CrossRef
103.
DiMeo T, Anderson K, Phadke P, Fan C, Feng C, Perou C, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Can Res. 2009;69(13):5364–73.CrossRef
104.
Marotta L, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24− stem cell-like breast cancer cells in human tumors. J Clin Investig. 2011;121(7):2723–35.PubMedPubMedCentralCrossRef
105.
Lynce F, Williams J, Regan M, Bunnell C, Freedman R, Tolaney S, et al. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021;87(5):673–9.PubMedCrossRef
106.
Lewis K, Bharadwaj U, Eckols T, Kolosov M, Kasembeli M, Fridley C, et al. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lung Cancer. 2015;90(2):182–90.PubMedCrossRef
107.
Bharadwaj U, Eckols T, Xu X, Kasembeli M, Chen Y, Adachi M, et al. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016;7(18):26307–30.PubMedPubMedCentralCrossRef
108.
Jung K, Yoo W, Stevenson H, Deshpande D, Shen H, Gagea M, et al. Multifunctional effects of a small-molecule STAT3 inhibitor on NASH and hepatocellular carcinoma in mice. Clin Cancer Res. 2017;23(18):5537–46.PubMedPubMedCentralCrossRef
109.
Kettner N, Vijayaraghavan S, Durak M, Bui T, Kohansal M, Ha M, et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res. 2019;25(13):3996–4013.PubMedPubMedCentralCrossRef
110.
Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug development in oncology. Onco Targets Ther. 2013;9:1285–304.PubMedCrossRef
111.
Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102(1):33–42.PubMedCrossRef
112.
Chai J, Du C, Wu J, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 2000;406(6798):855–62.PubMedCrossRef
113.
Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;54(8):2714–26.PubMedPubMedCentralCrossRef
114.
Hurwitz H, Smith D, Pitot H, Brill J, Chugh R, Rouits E, et al. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharmacol. 2015;75(4):851–9.PubMedPubMedCentralCrossRef
115.
Bardia A, Parton M, Kümmel S, Estévez L, Huang C, Cortés J, et al. Paclitaxel With inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial. J Clin Oncol. 2018:JCO2017748392.
116.
Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs. 2004;15(7):651–62.PubMedCrossRef
117.
Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat shock proteins and cancer. Trends Pharmacol Sci. 2017;38(3):226–56.PubMedCrossRef
118.
Woodhead A, Angove H, Carr M, Chessari G, Congreve M, Coyle J, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem. 2010;53(16):5956–69.PubMedCrossRef
119.
Shapiro G, Kwak E, Dezube B, Yule M, Ayrton J, Lyons J, et al. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):87–97.PubMedCrossRef
120.
Do K, Speranza G, Chang L, Polley E, Bishop R, Zhu W, et al. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Invest New Drugs. 2015;33(4):921–30.PubMedPubMedCentralCrossRef
121.
Kim J, Cho T, Park J, Park S, Park M, Nam K, et al. A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response. Oncogene. 2022;41(23):3289–97.PubMedPubMedCentralCrossRef
122.
Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, et al. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resist Updat. 2017;32:1–15.PubMedCrossRef
123.
124.
Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Investig. 2019;129(4):1785–800.PubMedPubMedCentralCrossRef
125.
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66.PubMedPubMedCentralCrossRef
126.
Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman D, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomark Prev. 2014;23(12):2965–70.CrossRef
127.
Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34(21):2460–7.PubMedPubMedCentralCrossRef
128.
Emens L, Cruz C, Eder J, Braiteh F, Chung C, Tolaney S, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82.PubMedCrossRef
129.
130.
Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714.PubMedCrossRef
131.
132.
Dieci M, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Annals Oncol. 2014;25(3):611–8.CrossRef
133.
Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Science translational medicine. 2017;9(393).
134.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.PubMedCrossRef
135.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Annals Oncol. 2021;32(8):994–1004.CrossRef
136.
Mittendorf E, Zhang H, Barrios C, Saji S, Jung K, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–100.PubMedCrossRef
137.
Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–28.PubMedCrossRef
138.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21.PubMedCrossRef
139.
Winer E, Lipatov O, Im S, Goncalves A, Muñoz-Couselo E, Lee K, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499–511.PubMedCrossRef
140.
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M, Hsu J, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–20.PubMedPubMedCentralCrossRef
141.
Jiao X, Wang M, Zhang Z, Li Z, Ni D, Ashton A, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021;23(1):11.PubMedPubMedCentralCrossRef
142.
143.
Massimo Cristofanilli, Milana Dolezal, Jay Lalezari, Hallgeir Rui, Bruce Patterson, Cha-Mei Tang, Daniel Adams, Qiang Zhang, Kazem Kazempour, Nader Pourhassan, Natalie Rabb, Kush Dhody. Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27–28 and Jun 22–24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT233.
144.
Yoo C, Oh D, Choi H, Kudo M, Ueno M, Kondo S, et al. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer. 2020;8(1):e000564.PubMedPubMedCentralCrossRef
145.
Paz-Ares L, Kim T, Vicente D, Felip E, Lee D, Lee K, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial. J Thoracic Oncol. 2020;15(7):1210–22.CrossRef
146.
Cho B, Daste A, Ravaud A, Salas S, Isambert N, McClay E, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer. 2020;8(2):e000664.PubMedPubMedCentralCrossRef
147.
Alexander Spira, Ahmad Awada, Nicolas Isambert, David Lorente Estellés, John Nemunaitis, Nicolas Penel, Laureen S Ojalvo, Christoph Helwig, Christian Borel. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-β and programmed death ligand 1, in advanced triple-negative breast cancer: Preliminary results from a phase 1 cohort [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10–14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):P3-09-06.
148.
Caiazza F, McGowan P, Mullooly M, Murray A, Synnott N, O’Donovan N, et al. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. Br J Cancer. 2015;112(12):1895–903.PubMedPubMedCentralCrossRef
149.
Yamamoto K, Trad A, Baumgart A, Hüske L, Lorenzen I, Chalaris A, et al. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J. 2012;445(1):135–44.PubMedCrossRef
150.
Dees S, Ganesan R, Singh S, Grewal I. Bispecific antibodies for triple negative breast cancer. Trends in cancer. 2021;7(2):162–73.PubMedCrossRef
151.
Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody–drug conjugates: recent advances in linker chemistry. Acta Pharm Sinica B. 2021;11(12):3889–907.CrossRef
152.
Sharkey R, McBride W, Cardillo T, Govindan S, Wang Y, Rossi E, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res. 2015;21(22):5131–8.PubMedCrossRef
153.
Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35(19):2141–8.PubMedPubMedCentralCrossRef
154.
155.
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–51.PubMedCrossRef
156.
Carey L, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022;8(1):72.PubMedPubMedCentralCrossRef
157.
Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Science translational medicine. 2017;9(372).
158.
Maitland M, Sachdev J, Sharma M, Moreno V, Boni V, Kummar S, et al. First-in-human study of PF-06647020 (Cofetuzumab Pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors. Clin Cancer Res. 2021;27(16):4511–20.PubMedCrossRef
159.
Zhang C, Sheng W, Al-Rawe M, Mohiuddin T, Niebert M, Zeppernick F, et al. EpCAM- and EGFR-specific antibody drug conjugates for triple-negative breast cancer treatment. Int J Mol Sci. 2022;23(11):6122.PubMedPubMedCentralCrossRef
160.
Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, et al. EMERGE: a randomized phase II Study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol. 2015;33(14):1609–19.PubMedCrossRef
161.
Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, et al. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2014;32(32):3619–25.PubMedCrossRef
162.
Vahdat L, Schmid P, Forero-Torres A, Blackwell K, Telli M, Melisko M, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study. NPJ Breast Cancer. 2021;7(1):57.PubMedPubMedCentralCrossRef
163.
Yao H, Suthe S, Hudson R, Wang M. Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer. Drug Discov Today. 2020;25(7):1160–73.PubMedCrossRef
164.
Nicolazzi C, Caron A, Tellier A, Trombe M, Pinkas J, Payne G, et al. An antibody-drug conjugate targeting MUC1-associated carbohydrate CA6 shows promising antitumor activities. Mol Cancer Ther. 2020;19(8):1660–9.PubMedCrossRef
165.
Demeule M, Charfi C, Currie J, Larocque A, Zgheib A, Kozelko S, et al. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021;112(10):4317–34.PubMedPubMedCentralCrossRef
166.
Boni V, Fidler M, Arkenau H, Spira A, Meric-Bernstam F, Uboha N, et al. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial. Clin Cancer Res Offl J Am Assoc Cancer Res. 2022;28(10):2020–9.CrossRef
167.
Vogl D, Kaufman J, Holstein S, Nadeem O, O’Donnell E, Suryanarayan K, Collins S, Parot X, Chaudhry M. TAK-573, an anti-CD38/attenuated Ifnα fusion protein, has clinical activity and modulates the Ifnα receptor (IFNAR) pathway in patients with relapsed/refractory multiple myeloma. Blood. 2020;136:37–8. https://​doi.​org/​10.​1182/​blood-2020-141219.CrossRef
168.
Duca M, Lim D, Subbiah V, Takahashi S, Sarantopoulos J, Varga A, et al. A first-in-human, phase I, multicenter, open-label, dose-escalation study of PCA062: an antibody-drug conjugate targeting p-cadherin, in patients with solid tumors. Mol Cancer Ther. 2022;21(4):625–34.PubMedCrossRef
169.
Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G, Fusco N. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opin Investig Drugs. 2022;31(6):593–605.PubMedCrossRef
170.
Tchou J, Zhao Y, Levine B, Zhang P, Davis M, Melenhorst J, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res. 2017;5(12):1152–61.PubMedPubMedCentralCrossRef
171.
Cha J, Chan L, Wang Y, Chu Y, Wang C, Lee H, et al. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem. 2022;298(4):101817.PubMedPubMedCentralCrossRef
172.
173.
Seitz C, Schroeder S, Knopf P, Krahl A, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9(1):1683345.PubMedCrossRef
174.
Wei H, Wang Z, Kuang Y, Wu Z, Zhao S, Zhang Z, et al. Intercellular adhesion molecule-1 as target for CAR-T-cell therapy of triple-negative breast cancer. Front Immunol. 2020;11:573823.PubMedPubMedCentralCrossRef
175.
Santoni M, Romagnoli E, Saladino T, Foghini L, Guarino S, Capponi M, et al. Triple negative breast cancer: key role of tumor-associated macrophages in regulating the activity of anti-PD-1/PD-L1 agents. Biochim Biophys Acta. 2018;1869(1):78–84.
Metadata
Title
Recent advances in therapeutic strategies for triple-negative breast cancer
Authors
Yun Li
Huajun Zhang
Yulia Merkher
Lin Chen
Na Liu
Sergey Leonov
Yongheng Chen
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01341-0

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Letter to the Editor

HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk

Review

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment

Review

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

Correspondence

FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study

Letter to the Editor

Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment

Review

Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits